Ascent Group LLC acquired a new position in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,772 shares of the company stock, valued at approximately $ 1,776,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Family CFO Inc purchased a new stake in Johnson & Johnson during the fourth quarter worth approximately $ 26,000. Steward Financial Group LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $ 34,000. Jackson Wealth Management LLC lifted its position in shares of Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company stock worth $ 40,000 after purchasing an additional 277 shares in the last quarter. Iron Horse Wealth Management LLC lifted its position in shares of Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company stock worth $ 45,000 after purchasing an additional 61 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Johnson & Johnson by 290.7% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company stock worth $ 47,000 after purchasing an additional 218 shares in the last quarter. Institutional investors own 68.78% of the company stock.
JNJ has been the topic of a number of recent research reports. Bank of America initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating on the stock. Citigroup reduced their target price on shares of Johnson & Johnson from $ 210.00 to $ 205.00 in a research report on Tuesday, May 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Sanford C. Bernstein cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price target for the company from $ 180.00 to $ 183.00 in a report on Wednesday, March 16th. Finally, The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $ 163.00 to $ 181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $ 190.50.
JNJ stock opened at $ 169.46 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. Johnson & Johnson has a 1-year low of $ 155.72 and a 1-year high of $ 186.69. The firm has a fifty day moving average price of $ 178.10 and a two-hundred day moving average price of $ 172.79. The firm has a market cap of $ 445.92 billion, a price-to-earnings ratio of 22.84, a PEG ratio of 3.36 and a beta of 0.66.
Johnson & Johnson (NYSE: JNJ – Get Rating) last released its earnings results on Tuesday, April 19th. The company reported $ 2.67 earnings per share for the quarter, beating the consensus estimate of $ 2.60 by $ 0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The firm had revenue of $ 23.43 billion during the quarter, compared to analyst estimates of $ 23.62 billion. During the same quarter in the previous year, the firm earned $ 2.59 earnings per share. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were paid a dividend of $ 1.13 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $ 1.06. The ex-dividend date was Monday, May 23rd. This represents a $ 4.52 annualized dividend and a yield of 2.67%. Johnson & Johnson’s payout ratio is presently 60.92%.
In other news, CAO Robert J. Decker sold 8,462 shares of the company stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $ 180.00, for a total transaction of $ 1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $ 2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $ 173.00, for a total transaction of $ 6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company stock, valued at approximately $ 12,336,803. The disclosure for this sale can be found here. In the last quarter, insiders have sold 78,161 shares of company stock valued at $ 13,895,302. 0.35% of the stock is owned by insiders.
Johnson & Johnson Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More:
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
.